Why the study?
Does amiodarone control symptomatic arrhythmias in patients refractory to standard antiarrhythmic therapies?
Does amiodarone control symptomatic arrhythmias in patients refractory to standard antiarrhythmic therapies?
Amiodarone is highly effective in controlling severe, symptomatic supraventricular and ventricular arrhythmias that are refractory to multiple standard antiarrhythmic therapies.
Answers are grounded in this paper and cite their sources.
Amiodarone may control refractory SVT attacks and admissions; leaves open confirmation in controlled trials.
Amiodarone hydrochloride was used to treat 19 patients with symptomatic arrhythmias refractory to quinidine sulfate, procainamide hydrochloride, disopyramide phosphate, antazoline hydrochloride, lidocaine hydrochloride, bretylium tosylate, propranolol hydrochloride, phenytoin sodium, and practotol acetanilide given to the limit of tolerance. In 17 patients, attacks were completely controlled. Arrhythmias treated successfully included recurrent supraventricular tachycardias, recurrent supraventricular tachycardias with Wolff-Parkinson-White syndrome, and refractory ventricular arrhythmias including recurrent ventricular tachycardia and ventricular fibrillation complicating acute coronary heart disease. Control was confirmed by continuous ECG monitoring both in the hospital and when ambulatory and was maintained for up to four years. Attacks of supraventricular tachycardia were reduced from 7.9/mo to one attack every 53.5 months on amiodarone. Hospital admissions for arrhythmias were reduced from 34 the year before treatment to none the year after. Therefore, amiodarone is an excellent drug for control of many refractory arrhythmias, but two patients with recurrent atrial fibrillation were refractory to this treatment.
No takes yet. Share an insight, caveat, or question.
David J. Leak (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: